The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Gene Therapy On Neurological Diseases Market In 2026 And How Much Will It Reach By 2030?
The gene therapy on neurological diseases market size has experienced rapid expansion in recent years. It is projected to increase from $3.55 billion in 2025 to $4.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. The historical growth can be attributed to factors including the limited gene therapy options available for neurological diseases, the rising prevalence of Alzheimer’s and Parkinson’s disease, the reliance on conventional treatment methods, increasing awareness of genetic approaches, and early clinical trials of viral vectors.
The market for gene therapy targeting neurological diseases is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $6.48 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 12.7%. This growth during the forecast period can be primarily attributed to factors such as advancements in adeno-associated virus and lentiviral therapies, the broadening of non-viral delivery platforms, an increase in regulatory approvals for neurological gene treatments, escalating investments in research and development for precise genetic interventions, and the incorporation of digital monitoring along with AI-driven patient management systems. Key trends expected during the forecast timeframe encompass increased funding for both viral and non-viral gene therapy platforms, the broadening of gene therapy applications to cover a wider range of neurological disorders, a heightened emphasis on individualized and targeted genetic therapies, the expansion of gene therapy initiatives within hospitals and clinics, and the innovation of sophisticated delivery techniques for neurological gene therapy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp
What Important Drivers Are Powering The Gene Therapy On Neurological Diseases Market Growth?
The expanding occurrence of neurological disorders is anticipated to stimulate the growth of the gene therapy on neurological diseases market. These conditions are medical issues impacting the brain, spinal cord, and nerves, resulting in various cognitive, motor, and sensory difficulties. The rising incidence is connected to an aging demographic, as aging progressively impairs neuronal function, diminishes brain plasticity, and elevates oxidative stress, all contributing to the onset and progression of these ailments. Gene therapy on neurological diseases assists in managing these disorders by targeting their underlying genetic origins, providing potential lasting or permanent treatment options. It enhances patient results through restoring or altering gene function, alleviating symptoms, and lessening the need for repeated medical procedures, thus improving the overall quality of life. For example, in July 2024, the National Health Service, a UK-based government agency, reported 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the increasing prevalence of neurological disorders is fueling the expansion of the gene therapy on neurological diseases market.
Which Segment Divisions Form The Structure Of The Gene Therapy On Neurological Diseases Market?
The gene therapy on neurological diseases market covered in this report is segmented –
1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy
2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis
3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus
2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)
What Trends Are Influencing The Gene Therapy On Neurological Diseases Market Outlook?
Major companies operating in the gene therapy on neurological diseases market are focusing on developing advanced viral delivery systems, such as adeno-associated virus serotype 2 (AAV2) vector. This development aims to improve targeted gene delivery, enhance efficacy, reduce immune reactions, and enable long-lasting treatments. The adeno-associated virus serotype 2 (AAV2) vector itself is a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into target cells, particularly neurons, for long-term expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for a gene therapy designed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy utilizes an AAV2 vector to deliver a functional copy of the DDC gene into the putamen, enabling dopamine production and improving motor functions. It features a one-time, intraputaminal infusion engineered to provide sustained therapeutic benefits, significantly enhancing motor function and reducing debilitating symptoms without the need for repeated interventions.
Which Firms Are Competing In The Gene Therapy On Neurological Diseases Market?
Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
Access The Complete Gene Therapy On Neurological Diseases Market Report:
Which Region Contributes The Most To The Gene Therapy On Neurological Diseases Market?
North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Gene Therapy On Neurological Diseases Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp
Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company
Switchboard Market Report 2026
https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report
Mobile Computer Market 2026
https://www.thebusinessresearchcompany.com/report/mobile-computer-market
Surfing Boards Market Report 2026
https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model